EA200900925A1 - 3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов - Google Patents

3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов

Info

Publication number
EA200900925A1
EA200900925A1 EA200900925A EA200900925A EA200900925A1 EA 200900925 A1 EA200900925 A1 EA 200900925A1 EA 200900925 A EA200900925 A EA 200900925A EA 200900925 A EA200900925 A EA 200900925A EA 200900925 A1 EA200900925 A1 EA 200900925A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
brain
benzotriazinous
substitute
increasing
Prior art date
Application number
EA200900925A
Other languages
English (en)
Other versions
EA017437B1 (ru
Inventor
Алексис Корди
Гэри Роджерс
Рудольф Мюллер
Original Assignee
Кортекс Фармасьютиклз, Инк.
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кортекс Фармасьютиклз, Инк., Ле Лаборатуар Сервье filed Critical Кортекс Фармасьютиклз, Инк.
Publication of EA200900925A1 publication Critical patent/EA200900925A1/ru
Publication of EA017437B1 publication Critical patent/EA017437B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к предотвращению и лечению мозговой недостаточности, включая увеличение функционирования рецептора в синапсах, в ячеистых структурах мозга, ответственных за поведения более высокого порядка. Эти ячеистые структуры мозга включены в познавательные способности, связанные с нарушением памяти, такого как наблюдается при различных слабоумиях, и в дисбалансе в нейронной активности между разными участками мозга, который предполагается в нарушениях, таких как болезнь Паркинсона, шизофрения и аффективные нарушения. В особенном объекте настоящее изобретение относится к соединению, пригодному для лечения таких патологических состояний, и способам применения этих соединений для такого лечения.
EA200900925A 2007-01-03 2007-12-28 3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов EA017437B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
EA200900925A1 true EA200900925A1 (ru) 2009-12-30
EA017437B1 EA017437B1 (ru) 2012-12-28

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900925A EA017437B1 (ru) 2007-01-03 2007-12-28 3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов

Country Status (38)

Country Link
US (1) US8173644B2 (ru)
EP (1) EP2144506B1 (ru)
JP (1) JP5139446B2 (ru)
CN (1) CN101616592B (ru)
AP (1) AP2502A (ru)
AR (1) AR064740A1 (ru)
AT (1) ATE527269T1 (ru)
AU (1) AU2007342365B2 (ru)
BR (1) BRPI0720749A2 (ru)
CA (1) CA2674460C (ru)
CR (1) CR10906A (ru)
CU (1) CU23804B7 (ru)
CY (1) CY1112493T1 (ru)
DK (1) DK2144506T3 (ru)
EA (1) EA017437B1 (ru)
EC (1) ECSP099499A (ru)
ES (1) ES2374995T3 (ru)
GE (1) GEP20125438B (ru)
GT (1) GT200900189A (ru)
HK (1) HK1140105A1 (ru)
HN (1) HN2009001268A (ru)
HR (1) HRP20110970T1 (ru)
IL (1) IL199651A (ru)
MA (1) MA31160B1 (ru)
ME (1) ME00819B (ru)
MX (1) MX2009007242A (ru)
MY (1) MY154877A (ru)
NI (1) NI200900131A (ru)
NZ (1) NZ578293A (ru)
PL (1) PL2144506T3 (ru)
PT (1) PT2144506E (ru)
RS (1) RS52108B (ru)
SG (1) SG163545A1 (ru)
SI (1) SI2144506T1 (ru)
SV (1) SV2009003322A (ru)
TN (1) TN2009000277A1 (ru)
WO (1) WO2008085506A1 (ru)
ZA (1) ZA200904826B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090098999A (ko) * 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2013075624A1 (zh) 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
PT1156043E (pt) 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
ES2128629T3 (es) * 1994-10-31 1999-05-16 Merck Patent Gmbh Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos.
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
EP1448537A4 (en) * 2001-11-26 2005-05-04 Cortex Pharma Inc CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
NZ540468A (en) * 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR20090098999A (ko) 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
MX2010002890A (es) * 2007-09-20 2010-07-02 Cortex Pharma Inc 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.

Also Published As

Publication number Publication date
PL2144506T3 (pl) 2012-04-30
MY154877A (en) 2015-08-14
EP2144506A1 (en) 2010-01-20
GT200900189A (es) 2011-08-02
PT2144506E (pt) 2011-12-21
US8173644B2 (en) 2012-05-08
CR10906A (es) 2009-10-23
WO2008085506A1 (en) 2008-07-17
ATE527269T1 (de) 2011-10-15
SG163545A1 (en) 2010-08-30
TN2009000277A1 (en) 2010-10-18
AU2007342365A1 (en) 2008-07-17
CN101616592A (zh) 2009-12-30
AP2502A (en) 2012-10-23
HK1140105A1 (en) 2010-10-08
DK2144506T3 (da) 2012-03-05
CU20090117A7 (es) 2011-10-05
AU2007342365B2 (en) 2012-11-15
CY1112493T1 (el) 2015-12-09
AP2009004931A0 (en) 2009-08-31
CN101616592B (zh) 2013-06-05
SI2144506T1 (sl) 2012-01-31
ME00819B (me) 2012-03-20
JP2010514838A (ja) 2010-05-06
ECSP099499A (es) 2009-10-30
MA31160B1 (fr) 2010-02-01
MX2009007242A (es) 2009-09-02
NZ578293A (en) 2012-01-12
HRP20110970T1 (hr) 2012-01-31
IL199651A (en) 2015-08-31
AR064740A1 (es) 2009-04-22
ZA200904826B (en) 2010-09-29
US20100137295A1 (en) 2010-06-03
CA2674460A1 (en) 2008-07-17
HN2009001268A (es) 2011-12-27
CA2674460C (en) 2014-07-15
NI200900131A (es) 2010-03-11
EP2144506B1 (en) 2011-10-05
SV2009003322A (es) 2010-02-05
IL199651A0 (en) 2010-04-15
EA017437B1 (ru) 2012-12-28
JP5139446B2 (ja) 2013-02-06
BRPI0720749A2 (pt) 2014-01-14
ES2374995T3 (es) 2012-02-23
GEP20125438B (en) 2012-03-26
EP2144506A4 (en) 2010-05-05
RS52108B (en) 2012-08-31
CU23804B7 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
EA200900925A1 (ru) 3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
WO2007009083A3 (en) Compounds with activity at retinoic acid receptors
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
EA201491534A1 (ru) Ингибиторы бета-секретазы
EP2604602A4 (en) HETEROARYLPYRAZOLDERIVAT
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
Karakuła-Juchnowicz et al. New prospects for antipsychotic treatment-the role of the kynurenine pathway
GEP20063859B (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
EA201690971A1 (ru) ПИРИДО[4,3-b]ПИРАЗИН-2-КАРБОКСАМИДЫ В КАЧЕСТВЕ НЕЙРОГЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
EA201101162A1 (ru) Производные бициклического амида для усиления глутаматергических синаптических ответов
Waselius Somatosensory evoked potentials as indicators of aging-related changes in sensory-cognitive functions
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
TH127359B (th) อนุพันธ์ 1,2,4-ไตรอะโซโล[4,3-a]ไพริดีนและการใช้มันในฐานะโพสิทิฟ อัลโลสเตริก มอดูเลเตอร์ ของหน่วยรับความรู้สึก MGLUR2
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
TH133721B (th) ไทอินิล-และ ฟูรานิล-ไอโซควิโนลิโนน และวิธีสำหรับการใช้งานของสิ่งเหล่านั้น

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU